We are Sarepta Therapeutics: a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. Our primary focus is on rapidly advancing the development of our potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.
Our commitment to the patients and families impacted by Duchenne muscular dystrophy extends beyond treatment. We are proud to offer SareptAssist™, a patient support program for those seeking information on therapy.
Our unique RNA-based technology has the potential to advance treatments in numerous areas of high unmet need. We are continuing to advance our clinical programs for Duchenne muscular dystrophy.
We seek collaborations with leaders in industry, government, and academia to make meaningful advances in medicine. Our proprietary and highly versatile RNA-based technologies form the foundation of our partnering strategy.